Our lead therapeutic candidate, LB1148, is a patent-protected formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive enzymes that can seriously damage tissues and organs throughout the body if they escape the intestines through a compromised mucosal barrier.
The therapy is being developed for administered prior to major surgeries that are risks of disrupting the intestinal mucosal barrier. In this setting, the treatment is administered orally via a liquid formulation equivalent to the size of a can of soda. It then travels to the gastrointestinal (GI) tract where it temporarily inhibits the activity of 17 digestive proteases, mitigating the risk of medical complications should those proteases escape the intestines and enter the surrounding tissues and lymphatic system.
Our initial focus is combatting the interruption of GI function (ileus) following major surgery to shorten patients’ length of stay in the hospital. Economically, this intervention is critically important since interruption of GI function (ileus) extends recovery times for patients, significantly increasing the length of hospital stay.